Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2020 1
2021 2
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.
Philipp N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, Scheurer M, Muth A, Hänel G, Nixdorf D, Sponheimer M, Ohlmeyer M, Lacher SM, Brauchle B, Marcinek A, Rohrbacher L, Leutbecher A, Rejeski K, Weigert O, von Bergwelt-Baildon M, Theurich S, Kischel R, Jeremias I, Bücklein V, Subklewe M. Philipp N, et al. Among authors: brauchle b. Blood. 2022 Sep 8;140(10):1104-1118. doi: 10.1182/blood.2022015956. Blood. 2022. PMID: 35878001 Free PMC article.
CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Marcinek A, Brauchle B, Rohrbacher L, Hänel G, Philipp N, Märkl F, Strzalkowski T, Lacher SM, Udiljak D, Spiekermann K, Theurich S, Kobold S, Kischel R, James JR, Bücklein VL, Subklewe M. Marcinek A, et al. Among authors: brauchle b. Cancer Immunol Immunother. 2023 Jul;72(7):2499-2512. doi: 10.1007/s00262-023-03439-x. Epub 2023 Apr 11. Cancer Immunol Immunother. 2023. PMID: 37041225 Free PMC article.
A modular and controllable T cell therapy platform for acute myeloid leukemia.
Benmebarek MR, Cadilha BL, Herrmann M, Lesch S, Schmitt S, Stoiber S, Darwich A, Augsberger C, Brauchle B, Rohrbacher L, Oner A, Seifert M, Schwerdtfeger M, Gottschlich A, Rataj F, Fenn NC, Klein C, Subklewe M, Endres S, Hopfner KP, Kobold S. Benmebarek MR, et al. Among authors: brauchle b. Leukemia. 2021 Aug;35(8):2243-2257. doi: 10.1038/s41375-020-01109-w. Epub 2021 Jan 7. Leukemia. 2021. PMID: 33414484 Free PMC article.
Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia.
Brauchle B, Goldstein RL, Karbowski CM, Henn A, Li CM, Bücklein VL, Krupka C, Boyle MC, Koppikar P, Haubner S, Wahl J, Dahlhoff C, Raum T, Rardin MJ, Sastri C, Rock DA, von Bergwelt-Baildon M, Frank B, Metzeler KH, Case R, Friedrich M, Balazs M, Spiekermann K, Coxon A, Subklewe M, Arvedson T. Brauchle B, et al. Mol Cancer Ther. 2020 Sep;19(9):1875-1888. doi: 10.1158/1535-7163.MCT-19-1093. Epub 2020 Jun 9. Mol Cancer Ther. 2020. PMID: 32518207
Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Marcinek A, Brauchle B, Rohrbacher L, Hänel G, Philipp N, Märkl F, Strzalkowski T, Lacher SM, Udiljak D, Spiekermann K, Theurich S, Kobold S, Kischel R, James JR, Bücklein VL, Subklewe M. Marcinek A, et al. Among authors: brauchle b. Cancer Immunol Immunother. 2023 Jul;72(7):2513-2514. doi: 10.1007/s00262-023-03457-9. Cancer Immunol Immunother. 2023. PMID: 37154851 Free PMC article. No abstract available.